Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

被引:2
|
作者
Ding, Shuo [1 ]
Guo, Wei [1 ]
Yin, Gaofei [1 ]
Li, Nuan [1 ]
Liu, Hongfei [1 ]
Huang, Junwei [1 ]
Yang, Zheng [1 ]
Xu, Hongbo [1 ]
Chen, Xiaohong [1 ]
Zhang, Yang [1 ]
Huang, Zhigang [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Squamous cell carcinoma of head and neck; clinical pathology; clinical protocols; SURVIVAL; CANCER;
D O I
10.21037/atm-22-2630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients. Methods: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I-IV, T1-4a, N0-2, M0). The intervention treatment methods for stage I-II patients are as follows: surgery, induction chemotherapy (IC) + surgery; surgery + adjuvant therapy; The intervention treatment methods for stage III-IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. Results: From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%. Conclusions: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] A prospective study of intraoperative assessment of mucosal squamous cell carcinoma margins in the head and neck
    Smithers, Fiona A. E.
    Haymerle, Georg
    Palme, Carsten E.
    Low, Tsu-Hui
    Froggatt, Catriona
    Gupta, Ruta
    Clark, Jonathan R.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (02): : 590 - 600
  • [2] A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma
    Codd, JD
    Salisbury, JR
    Packham, G
    Nicholson, LJ
    [J]. JOURNAL OF PATHOLOGY, 1999, 187 (05): : 549 - 555
  • [3] Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study
    Macedo, Ligia Traldi
    Costa, Ericka Francislaine Dias
    Carvalho, Bruna Fernandes
    Lourenco, Gustavo Jacob
    Calonga, Luciane
    Castilho, Arthur Menino
    Chone, Carlos Takahiro
    Lima, Carmen Silvia Passos
    [J]. CANCERS, 2023, 15 (06)
  • [4] A study of TRAIL receptors in squamous cell carcinoma of the head and neck
    Teng, MS
    Brandwein-Gensler, MS
    Teixeira, MS
    Martignetti, JA
    Duffey, DC
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2005, 131 (05) : 407 - 412
  • [5] Tumor lymphangiogenesis in head and neck squamous cell carcinoma - A morphometric study with clinical correlations
    Franchi, A
    Gallo, O
    Massi, D
    Baroni, G
    Santucci, M
    [J]. CANCER, 2004, 101 (05) : 973 - 978
  • [6] PET/CT in Head and Neck Squamous Cell Carcinoma with an unknown Origin Significant diagnostic to be Recovered in a prospective clinical Study
    Schober, O.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (07) : 637 - 638
  • [7] A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma
    Sakso, Mette
    Andersen, Elo
    Bentzen, Jens
    Andersen, Maria
    Johansen, Jorgen
    Primdahl, Hanne
    Overgaard, Jens
    Eriksen, Jesper Grau
    [J]. ACTA ONCOLOGICA, 2019, 58 (10) : 1495 - 1501
  • [8] External carotid artery stenosis in patients with head and neck squamous cell carcinoma - A prospective study
    Brennan, P. A.
    [J]. ORAL ONCOLOGY, 2008, 44 (03) : 301 - 304
  • [9] A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma
    Wong, WL
    Chevretton, EB
    McGurk, M
    Hussain, K
    Davis, J
    Beaney, R
    Baddeley, H
    Tierney, P
    Maisey, M
    [J]. CLINICAL OTOLARYNGOLOGY, 1997, 22 (03) : 209 - 214
  • [10] Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study
    Hardman, John C.
    Constable, James
    Dobbs, Sian
    Hogan, Christopher
    Hulse, Kate
    Khosla, Shivun
    Milinis, Kristijonas
    Tudor-Green, Ben
    Williamson, Andrew
    Paleri, Vinidh
    [J]. CLINICAL OTOLARYNGOLOGY, 2024, 49 (05) : 604 - 620